Skip to content

Praxis Precision Medicines, Inc. PRAX Convertible Preferred Stock Authorized Shares

Convertible Preferred Stock Authorized Shares at other companies

Neurocrine Biosciences logo
Neurocrine BiosciencesNBIX
Rhythm Pharmaceuticals, Inc. logo
Rhythm Pharmaceuticals, Inc.RYTM
BridgeBio Pharma logo
BridgeBio PharmaBBIO

Other financials

Income statement

See full
Revenue--100%
Operating income-$105.9M-41.7%
Net income-$92.6M-33.6%
EPS (diluted)-$3.20+2.7%

Balance sheet

See full
Cash & equivalents$536.7M+223%
Total debt$1.4M+31.3%
Total equity$1.4B+221%
Total assets$1.5B+205%

Cash flow

See full
Operating cash flow-$86.2M-62.5%
CapEx$62.0K
Free cash flow-$86.2M-62.6%

Valuation

See full
Market cap$7.87B+1,075%
Enterprise value$7.34B+1,309%

Profitability

See full
Operating margin-3,927.5%-1,497pp
Net margin-3,658.5%-1,388pp
FCF margin-3,067.4%-1,030pp

Returns & leverage

See full
Return on equity-35.3%-10.9pp
Debt / equity0.0×
Current ratio15.9×+7.4×

Where this comes from

Reported directly by Praxis Precision Medicines, Inc. in its filing.

Tagged under the XBRL concept us-gaap:PreferredStockSharesAuthorized.

The official record: Praxis Precision Medicines, Inc.’s 10-Q, filed May 7, 2026, on SEC EDGAR. View the filing →

Ask your AI about Praxis Precision Medicines, Inc.'s convertible preferred stock authorized shares.

Connect your AI assistant and compare it to peers, right in your chat.

Connect your AI
Harbor at dusk
Claude

Questions, answered.

What is Praxis Precision Medicines, Inc.'s convertible preferred stock authorized shares?
Praxis Precision Medicines, Inc. (PRAX) reported convertible preferred stock authorized shares of 10M in Q1 2026.
How has Praxis Precision Medicines, Inc.'s convertible preferred stock authorized shares changed year-over-year?
Praxis Precision Medicines, Inc.'s convertible preferred stock authorized shares decreased by 0.0% year-over-year, from 10M to 10M.
What is the long-term trend for Praxis Precision Medicines, Inc.'s convertible preferred stock authorized shares?
Over 5 years (2020 to 2025), Praxis Precision Medicines, Inc.'s convertible preferred stock authorized shares has grown at a 0.0% compound annual growth rate (CAGR), from 10M to 10M.
What does convertible preferred stock authorized shares mean?
Maximum number of convertible preferred shares the company is authorized to issue under its corporate charter.